Donna S. Cox
- Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management 5
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 6
- Pharmaceutical Science top 5%
- Hematology top 5%
- Cancer Research top 10%
-
- Melanoma and MAPK Pathways 12
- PI3K/AKT/mTOR signaling in cancer 10
-
- Heparin-Induced Thrombocytopenia and Thrombosis 6
-
- Lung Cancer Treatments and Mutations 5
-
- Cancer Mechanisms and Therapy 5
-
- Biosimilars and Bioanalytical Methods 5
- Co-authors
- Natalie D. EddingtonHoward A. BurrisKenneth R. ScottJeffrey R. InfanteGary H. KamimoriRonald OtterstetterGregory BelenkyThomas J. Balkin
- Journals
- Journal of Clinical Oncology (7 papers)The Journal of Clinical Pharmacology (5 papers)British Journal of Clinical Pharmacology (2 papers)
- Partner nations
- United StatesUnited KingdomIndia
In The Last Decade
Donna S. Cox
53 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Internal Medicine 202
- Oncology 739
- Pharmaceutical Science 106
- Hematology 182
- Cancer Research 234
Countries citing papers authored by Donna S. Cox
This map shows the geographic impact of Donna S. Cox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna S. Cox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna S. Cox more than expected).
Fields of papers citing papers by Donna S. Cox
This network shows the impact of papers produced by Donna S. Cox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna S. Cox. The network helps show where Donna S. Cox may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Donna S. Cox, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 8 | |
| 2 | 2023 | 11 | |
| 3 | 2023 | 9 | |
| 4 | 2023 | 5 | |
| 5 | 2018 | 0 | |
| 6 | 2016 | 58 | |
| 7 | 2016 | 4 | |
| 8 | 2014 | 100 | |
| 9 | 2013 | 64 | |
| 10 | 2013 | 22 | |
| 11 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialbreakdown → | 2012 | 424 |
| 12 | 2010 | 50 | |
| 13 | 2008 | 27 | |
| 14 | 2005 | 13 | |
| 15 | 2002 | 47 | |
| 16 | 2002 | 273 | |
| 17 | 2002 | 83 | |
| 18 | 2001 | 40 | |
| 19 | 2000 | 107 | |
| 20 | 1999 | 23 |
About Donna S. Cox
Donna S. Cox is a scholar working on Internal Medicine, Pharmaceutical Science and Oncology, having authored 55 papers that have together received 2.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (12 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Heparin-Induced Thrombocytopenia and Thrombosis (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers), Venous Thromboembolism Diagnosis and Management (5 papers), Cancer Mechanisms and Therapy (5 papers) and Biosimilars and Bioanalytical Methods (5 papers). The work is most often cited by research in Internal Medicine (202 citations), Oncology (739 citations) and Pharmaceutical Science (106 citations). Donna S. Cox has collaborated with scholars based in United States, United Kingdom and India. Frequent co-authors include Natalie D. Eddington, Howard A. Burris, Kenneth R. Scott, Jeffrey R. Infante, Gary H. Kamimori, Ronald Otterstetter, Gregory Belenky, Thomas J. Balkin, Chetan S. Karyekar and Douglas J. DeMarini. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Clinical Pharmacology, British Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.